Landmark Clinical Trial Identifies Safer, Equally Effective Antibiotics for Staphylococcal Bloodstream Infections

Results from the global SNAP Trial, co-led by researchers at the Research Institute of the McGill University Health Centre, were simultaneously published in the New England Journal of Medicine and The Lancet. The study found that cefazolin and benzylpenicillin are safer and equally effective alternatives to cloxacillin, which has long been the default treatment for methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections. This research is expected to reshape treatment strategies for this life-threatening condition.